RxDoctor Payments Data

Timothy Lee, MD

Interventional Cardiology · Birmingham, ALNPI 1477588408

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $5,500 of the $8,091 with a category attached, or 68.0%. Merck accounts for 71.2% of it on its own, with 20 other manufacturers making up the rest. Reporting peaked in 2019 at $5,738 and has fallen 96.6% since, to $193 in 2025.

$8,091in general payments, 2019–2025

Across 88 payments — averaging $91.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$6K
  • Medtronic$1K
  • Novartis$264
  • Johnson & Johnson$209
  • Irhythm Technologies, Inc.$102
  • Boston Scientific$100
  • plus $442 from 15 others

What the payments were for

  • Consulting fees$5,50068%
  • Travel & lodging$79710%
  • Food & beverage$1,79322%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,091 in reported general payments places this provider in the 55th percentile of 109 interventional cardiology providers in Alabama.

See all interventional cardiology providers in Alabama

Medicare billing

Part B allowed, 2024
$70,854
Medicare patients
215
Services billed
879

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban67$64,250
EntrestoSacubitril/Valsartan16$13,252
Repatha SureclickEvolocumab13$9,494
Atorvastatin Calcium132$1,385
Losartan Potassium77$1,182
Ezetimibe15$572
Carvedilol69$552
Amiodarone Hcl14$409
Hydralazine Hcl40$357
Amlodipine Besylate45$325
Nitroglycerin12$294
ClopidogrelClopidogrel Bisulfate19$282
Olmesartan Medoxomil11$174
Isosorbide Mononitrate ErIsosorbide Mononitrate14$125
Lisinopril14$103

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$35$64,25067 claims
NovartisEntresto$264$13,25216 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 109 interventional cardiology providers in Alabama.

Other interventional cardiology in Birmingham

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →